Yesterday, March 3, 2016, 128 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $7.31 to $24,274,480.00.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 2,053 shares at $4.92 on March 3, 2016. Following this transaction, the SVP, Human Resources owned 195,340 shares meaning that the stake was reduced by 1.04% with the 2,053-share transaction.

Gleeson Michael, who is SVP, North American Com. Ops. at GenMark Diagnostics, sold 1,934 shares at $4.92 on March 3, 2016. Following this transaction, the SVP, North American Com. Ops. owned 255,157 shares meaning that the stake was reduced by 0.75% with the 1,934-share transaction.

Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 226 shares at $4.87 on March 3, 2016. Following this transaction, the SVP, International owned 138,891 shares meaning that the stake was reduced by 0.16% with the 226-share transaction.

Stier Eric, who is SVP & General Counsel at GenMark Diagnostics, sold 365 shares at $4.87 on March 3, 2016. Following this transaction, the SVP & General Counsel owned 112,189 shares meaning that the stake was reduced by 0.32% with the 365-share transaction.

The shares most recently traded at $6.37, up $1.50, or 23.55% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 4,500
  • 4-Week # shares sold: 697
  • 12-Week # shares bought: 4,500
  • 12-Week # shares sold: 23,568
  • 24-Week # shares bought: 13,500
  • 24-Week # shares sold: 36,380

The average volume for GenMark Diagnostics has been 217,300 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $226.2 million and is part of the health care sector and health services industry. Shares are down 20.88% year-to-date as of the close of trading on Thursday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings rates GenMark Diagnostics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full GenMark Diagnostics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DineEquity (DIN) - FREE Research Report

Rose Patrick W, who is Director at DineEquity, sold 3,000 shares at $93.01 on March 3, 2016. Following this transaction, the Director owned 44,137 shares meaning that the stake was reduced by 6.36% with the 3,000-share transaction.

The shares most recently traded at $94.13, up $1.12, or 1.19% since the insider transaction. Historical insider transactions for DineEquity go as follows:

  • 4-Week # shares bought: 41
  • 4-Week # shares sold: 1.0 million
  • 12-Week # shares bought: 41
  • 12-Week # shares sold: 1.0 million
  • 24-Week # shares bought: 41
  • 24-Week # shares sold: 1.0 million

The average volume for DineEquity has been 192,400 shares per day over the past 30 days. DineEquity has a market cap of $1.7 billion and is part of the services sector and leisure industry. Shares are up 9.78% year-to-date as of the close of trading on Thursday.

DineEquity, Inc., together with its subsidiaries, owns, franchises, and operates full-service restaurants in the United States and internationally. The stock currently has a dividend yield of 3.98%. The company has a P/E ratio of 16.8. Currently, there is 1 analyst who rates DineEquity a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DIN - FREE

TheStreet Quant Ratings rates DineEquity as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, notable return on equity and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full DineEquity Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CoreSite Realty (COR) - FREE Research Report

Tobin Dominic M., who is SVP, Operations at CoreSite Realty, sold 527 shares at $64.93 on March 3, 2016. Following this transaction, the SVP, Operations owned 44,902 shares meaning that the stake was reduced by 1.16% with the 527-share transaction.

McCandless Derek, who is General Counsel and SVP, Legal at CoreSite Realty, sold 790 shares at $64.80 on March 3, 2016. Following this transaction, the General Counsel and SVP, Legal owned 88,275 shares meaning that the stake was reduced by 0.89% with the 790-share transaction.

Warren Brian, who is SVP, Products & Marketing at CoreSite Realty, sold 267 shares at $64.39 on March 3, 2016. Following this transaction, the SVP, Products & Marketing owned 25,710 shares meaning that the stake was reduced by 1.03% with the 267-share transaction.

The shares most recently traded at $63.47, down $0.92, or 1.45% since the insider transaction. Historical insider transactions for CoreSite Realty go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 1,400
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 1,400
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 17,579

The average volume for CoreSite Realty has been 385,000 shares per day over the past 30 days. CoreSite Realty has a market cap of $2.0 billion and is part of the financial sector and real estate industry. Shares are up 13.28% year-to-date as of the close of trading on Thursday.

CoreSite Realty Corporation engages in the ownership, acquisition, construction, and management of data centers. The stock currently has a dividend yield of 3.29%. The company has a P/E ratio of 62.5. Currently, there are 5 analysts who rate CoreSite Realty a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COR - FREE

TheStreet Quant Ratings rates CoreSite Realty as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full CoreSite Realty Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.